Profile of:
Maureen Dubreuil
Dr. Dubreuil is a rheumatologist in Boston, specializing in Spondyloarthritis. She works within the Rheumatology sections at Boston University School of Medicine and VA Boston Healthcare System, where her research focuses on comorbidities and pharmacoepidemiology of spondyloarthritis. She has been the recipient of the Spondylitis Association of America Bruckel Early Career Investigator Award (2018), the Boston University Evans Junior Merit Award (2017), and a seed grant from the Spondyloarthritis Research and Treatment Network (SPARTAN; 2018). She currently serves on the Board, and as Education Chair for SPARTAN (2020-).
Full name: Maureen Dubreuil
Current country: United States
Membership level: Full
Type of membership: Member
Number of publications: 17
Mortality and Ankylosing Spondylitis in the US population: leading causes and associated factors. (2024)
https://pubmed.ncbi.nlm.nih.gov/37733078/
Trends in Fracture Rates Over Two Decades Among Veterans With Ankylosing Spondylitis. (2023)
https://pubmed.ncbi.nlm.nih.gov/37308459/
The role of upadacitinib for the treatment of axial spondyloarthritis. (2023)
https://pubmed.ncbi.nlm.nih.gov/37675498/
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. (2023)
https://pubmed.ncbi.nlm.nih.gov/36787993/
Social Media Use Among Members of the Assessment of Spondyloarthritis International Society: Results of a Web-Based Survey (2023)
https://pubmed.ncbi.nlm.nih.gov/36626201/
The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/34853088/
Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/34724089/
Risk factors for diagnosis of psoriatic arthritis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis: A set of parallel case-control studies (2022)
https://pubmed.ncbi.nlm.nih.gov/34334358/
Educational needs and challenges in axial spondyloarthritis. (2021)
https://pubmed.ncbi.nlm.nih.gov/33973547/
Relation of therapies for ankylosing spondylitis and psoriatic arthritis to risk of myocardial infarction: a nested case control study (2021)
https://pubmed.ncbi.nlm.nih.gov/34321112/
Relation of NSAIDs, DMARDs, and TNF Inhibitors for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Total Hip and Knee Arthroplasty (2021)
https://pubmed.ncbi.nlm.nih.gov/33452168/
Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis (2020)
https://pubmed.ncbi.nlm.nih.gov/31960614/
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions (2020)
https://pubmed.ncbi.nlm.nih.gov/32340706/
Effects of Therapies on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis (2020)
https://pubmed.ncbi.nlm.nih.gov/33170493/
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31436026/
Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic Research (2018)
https://pubmed.ncbi.nlm.nih.gov/29471586/
Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development (2017)
https://pubmed.ncbi.nlm.nih.gov/28376060/
